Summary
Quest Diagnostics Inc. (DGX) filed an 8-K on May 22, 2025, reporting the voting results from its 2025 Annual Meeting of Stockholders held on May 15, 2025. The filing confirms the election of all nominated directors to serve until the 2026 Annual Meeting, with overwhelming support from shareholders. Additionally, the advisory resolution on executive compensation was approved, reflecting shareholder confidence in the company's pay practices. The appointment of PricewaterhouseCoopers as the independent registered public accounting firm for 2025 also received strong ratification from stockholders. Notably, a stockholder proposal seeking the ability to call a special meeting did not pass, indicating that current governance structures remain favored by the majority. Overall, the results suggest a stable shareholder base supportive of current management and board leadership.
Key Highlights
- 1All director nominees were overwhelmingly elected for terms expiring at the 2026 Annual Meeting.
- 2The advisory resolution to approve executive officer compensation received strong shareholder support.
- 3PricewaterhouseCoopers was ratified as the independent registered public accounting firm for 2025 with substantial approval.
- 4A stockholder proposal to allow for calling special meetings failed to gain majority support.
- 5Broker non-votes were a significant factor in the director elections, though not enough to prevent any nominee's success.
- 6The voting demonstrates broad shareholder alignment with the company's current board and compensation practices.